NCT05040555View on ClinicalTrials.gov

R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden

NARecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2028

Conditions
Diffuse Large B Cell LymphomaFollicular Lymphoma Grade 3B
Interventions
COMBINATION_PRODUCT

R-CDOP

Rituximab 375mg/m2, D0; Cyclophosphamide 750mg/ m2, D1; Doxorubicin hydrochloride liposome 30-35mg/ m2, D1; Vindesine 3mg/ m2, D1; Prednisone 60mg/ m2, D1\~5.

Trial Locations (1)

130021

RECRUITING

The First Bethune Hospital of Jilin University, Changchun

All Listed Sponsors
lead

oubai, MD/PhD

OTHER